c3a neoepitope hm2074  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech c3a neoepitope hm2074
    C3a Neoepitope Hm2074, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c3a neoepitope hm2074/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c3a neoepitope hm2074 - by Bioz Stars, 2024-05
    94/100 stars

    Images

    c3a neoepitope hm2074  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech c3a neoepitope hm2074
    C3a Neoepitope Hm2074, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c3a neoepitope hm2074/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c3a neoepitope hm2074 - by Bioz Stars, 2024-05
    94/100 stars

    Images

    anti c3a neoepitope  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech anti c3a neoepitope
    Anti C3a Neoepitope, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a neoepitope/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a neoepitope - by Bioz Stars, 2024-05
    94/100 stars

    Images

    anti c3a desarg  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech anti c3a desarg
    Anti C3a Desarg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a desarg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a desarg - by Bioz Stars, 2024-05
    94/100 stars

    Images

    biotinylated c3a  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech biotinylated c3a
    Biotinylated C3a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biotinylated c3a/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    biotinylated c3a - by Bioz Stars, 2024-05
    94/100 stars

    Images

    hm2074  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech hm2074
    Hm2074, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm2074/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hm2074 - by Bioz Stars, 2024-05
    94/100 stars

    Images

    bh6 ic3b  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech bh6 ic3b
    Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.
    Bh6 Ic3b, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bh6 ic3b/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bh6 ic3b - by Bioz Stars, 2024-05
    94/100 stars

    Images

    1) Product Images from "Peripheral immune markers and antipsychotic non-response in psychosis"

    Article Title: Peripheral immune markers and antipsychotic non-response in psychosis

    Journal: Schizophrenia Research

    doi: 10.1016/j.schres.2020.12.020

    Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.
    Figure Legend Snippet: Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.

    Techniques Used:

    anti c3a des arg  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech anti c3a des arg
    Anti C3a Des Arg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a des arg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a des arg - by Bioz Stars, 2024-05
    94/100 stars

    Images

    mouse anti c3a  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech mouse anti c3a
    hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins <t>C3a</t> and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.
    Mouse Anti C3a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti c3a/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti c3a - by Bioz Stars, 2024-05
    94/100 stars

    Images

    1) Product Images from "Properdin Modulates Complement Component Production in Stressed Human Primary Retinal Pigment Epithelium Cells"

    Article Title: Properdin Modulates Complement Component Production in Stressed Human Primary Retinal Pigment Epithelium Cells

    Journal: Antioxidants

    doi: 10.3390/antiox9090793

    hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins C3a and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.
    Figure Legend Snippet: hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins C3a and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.

    Techniques Used: Expressing, Activation Assay, Cell Culture, Standard Deviation, Fluorescence

    hm2074-ia  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech hm2074-ia
    Hm2074 Ia, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm2074-ia/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hm2074-ia - by Bioz Stars, 2024-05
    93/100 stars

    Images

    monoclonal mouse antibody against human c3a c3a desarg  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech monoclonal mouse antibody against human c3a c3a desarg
    ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to <t>C3a</t> and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.
    Monoclonal Mouse Antibody Against Human C3a C3a Desarg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antibody against human c3a c3a desarg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal mouse antibody against human c3a c3a desarg - by Bioz Stars, 2024-05
    94/100 stars

    Images

    1) Product Images from "A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma"

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    Journal: Oncotarget

    doi: 10.18632/oncotarget.22963

    ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to C3a and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.
    Figure Legend Snippet: ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to C3a and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.

    Techniques Used: Activation Assay, Multiplex Assay, Luminex, Magnetic Beads, In Vitro

    ( A ) Serial dilutions of native, human C3a-desArg (black circle), recombinant, human C5a-desArg (black square) and native human sC5b-C9 (black triangle) depicted different assay performances for the simultaneous analysis of complement activation markers. The target antigens were only detected by respective coupled magnetic beads and not by control beads (grey). Limit of detection (orange) and assay cutoffs (red square) for each analyte are shown. ( B ) The concentration range of complement activation markers determined with the novel multiplex assay from a human serum pool (black square with dot) corresponded to previously reported ranges for C3a, C5a and sC5b-C9 single detection either from plasma (grey), serum (black) or unknown sample matrix (white), respectively [ – ].
    Figure Legend Snippet: ( A ) Serial dilutions of native, human C3a-desArg (black circle), recombinant, human C5a-desArg (black square) and native human sC5b-C9 (black triangle) depicted different assay performances for the simultaneous analysis of complement activation markers. The target antigens were only detected by respective coupled magnetic beads and not by control beads (grey). Limit of detection (orange) and assay cutoffs (red square) for each analyte are shown. ( B ) The concentration range of complement activation markers determined with the novel multiplex assay from a human serum pool (black square with dot) corresponded to previously reported ranges for C3a, C5a and sC5b-C9 single detection either from plasma (grey), serum (black) or unknown sample matrix (white), respectively [ – ].

    Techniques Used: Recombinant, Activation Assay, Magnetic Beads, Concentration Assay, Multiplex Assay

    ( A–C ) The histologic grade ( G ) describes the cell differentiation in the patients’ tumors/ neoplasms. Patients with G2 tumor grading had significantly elevated (A) C3a, as well as (B) C5a and (C) sC5b-9 serum levels compared to the control group. ( D–F ) The T-classification system categorizes the extension of the patients′ primary tumors. (D) There was no relation between C3a serum levels and T-classification. (E) All tumor extension classifications (T-classifications) showed a significant increase in systemic C5a levels compared to the control group. (F) Invasive growth (T4) is associated with increased sC5b-9 serum levels compared to the control, T2 and T3 group. ( G–J ) The N-classification describes the degree of spread of tumor cells to regional lymph nodes. (G) C3a concentration was significantly correlated with tumor spread to lymph nodes. C3a concentration was highest in N2 classified lymph node metastases. (H, I) There was no significant correlation between complement markers C5a, sC5b-C9 and lymph node metastases. (J) Patients, that presented a N2-tumor, were significantly younger than patients with a N0 or N1 tumor. ( K–M ) Age was not associated with T-classification or correlated with complement activation marker concentration in serum. ( * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 two-tailed, unpaired t -test).
    Figure Legend Snippet: ( A–C ) The histologic grade ( G ) describes the cell differentiation in the patients’ tumors/ neoplasms. Patients with G2 tumor grading had significantly elevated (A) C3a, as well as (B) C5a and (C) sC5b-9 serum levels compared to the control group. ( D–F ) The T-classification system categorizes the extension of the patients′ primary tumors. (D) There was no relation between C3a serum levels and T-classification. (E) All tumor extension classifications (T-classifications) showed a significant increase in systemic C5a levels compared to the control group. (F) Invasive growth (T4) is associated with increased sC5b-9 serum levels compared to the control, T2 and T3 group. ( G–J ) The N-classification describes the degree of spread of tumor cells to regional lymph nodes. (G) C3a concentration was significantly correlated with tumor spread to lymph nodes. C3a concentration was highest in N2 classified lymph node metastases. (H, I) There was no significant correlation between complement markers C5a, sC5b-C9 and lymph node metastases. (J) Patients, that presented a N2-tumor, were significantly younger than patients with a N0 or N1 tumor. ( K–M ) Age was not associated with T-classification or correlated with complement activation marker concentration in serum. ( * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 two-tailed, unpaired t -test).

    Techniques Used: Cell Differentiation, Concentration Assay, Activation Assay, Marker, Two Tailed Test

    ( A , B , D , F ) Specificity of C3a-beads, ( C , B, D, F) C5a-beads and ( E , B, D, F) sC5b-C9-beads were either analysed in a (A, C, E) one-bead assay with a single antigen dilution series or (B, D, F) all five bead regions and a singular antigen dilution series. (B, D, F) All beads showed a specific signal for the respective antigen and no cross reactivities. The detection of (A, B) C3a, (C, D) C5a and (E, F) sC5b-C9 was comparable in the (A, C, E) single and (B, D, F) multiplex assays, indicating a bead-specific detection.
    Figure Legend Snippet: ( A , B , D , F ) Specificity of C3a-beads, ( C , B, D, F) C5a-beads and ( E , B, D, F) sC5b-C9-beads were either analysed in a (A, C, E) one-bead assay with a single antigen dilution series or (B, D, F) all five bead regions and a singular antigen dilution series. (B, D, F) All beads showed a specific signal for the respective antigen and no cross reactivities. The detection of (A, B) C3a, (C, D) C5a and (E, F) sC5b-C9 was comparable in the (A, C, E) single and (B, D, F) multiplex assays, indicating a bead-specific detection.

    Techniques Used: Multiplex Assay

    ( A–C ) C3a, C5a and sC5b-C9 were quantified either in normal human control serum (control) or C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, properdin-, complement factor H-depleted serum. The lowest concentrations for (A) C3a and (B) C5a were observed in C3-depleted or C5-depleted serum, respectively. (C) The terminal complement complex was detected at a reduced level in C5-depleted serum. We did not observe a detection signal for any of the tested sera on the control beads (data not shown).
    Figure Legend Snippet: ( A–C ) C3a, C5a and sC5b-C9 were quantified either in normal human control serum (control) or C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, properdin-, complement factor H-depleted serum. The lowest concentrations for (A) C3a and (B) C5a were observed in C3-depleted or C5-depleted serum, respectively. (C) The terminal complement complex was detected at a reduced level in C5-depleted serum. We did not observe a detection signal for any of the tested sera on the control beads (data not shown).

    Techniques Used:

    C3a and C5a were either measured in ( A ) aqueous humor of glaucoma and cataract patients, ( B ) in tears of healthy controls or ( C–E ) in sera of OSCC-patients ( n = 57) and matched controls ( n = 46) using the validated 5-plex immunoassay based on luminex technology. (A) The C3a levels of glaucoma and cataract patients did not show any significant difference, but a tendency for higher C3a levels in glaucoma patients. C5a concentrations in aqueous humor were below the lower detection limit. (B) Quantification of C3a and C5a in tears ranged between 4.4–26 ng/mL for C3a and 0.11–3.3 ng/mL for C5a, respectively. (D, E) C5a and sC5b-C9 concentrations were significantly increased in OSCC patients compared to the control group. Mean with standard deviations are depicted. ( ** p < 0.01, **** p < 0.0001 two-tailed, unpaired t -test).
    Figure Legend Snippet: C3a and C5a were either measured in ( A ) aqueous humor of glaucoma and cataract patients, ( B ) in tears of healthy controls or ( C–E ) in sera of OSCC-patients ( n = 57) and matched controls ( n = 46) using the validated 5-plex immunoassay based on luminex technology. (A) The C3a levels of glaucoma and cataract patients did not show any significant difference, but a tendency for higher C3a levels in glaucoma patients. C5a concentrations in aqueous humor were below the lower detection limit. (B) Quantification of C3a and C5a in tears ranged between 4.4–26 ng/mL for C3a and 0.11–3.3 ng/mL for C5a, respectively. (D, E) C5a and sC5b-C9 concentrations were significantly increased in OSCC patients compared to the control group. Mean with standard deviations are depicted. ( ** p < 0.01, **** p < 0.0001 two-tailed, unpaired t -test).

    Techniques Used: Luminex, Two Tailed Test

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Hycult Biotech c3a neoepitope hm2074
    C3a Neoepitope Hm2074, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c3a neoepitope hm2074/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c3a neoepitope hm2074 - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech anti c3a neoepitope
    Anti C3a Neoepitope, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a neoepitope/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a neoepitope - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech anti c3a desarg
    Anti C3a Desarg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a desarg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a desarg - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech biotinylated c3a
    Biotinylated C3a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biotinylated c3a/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    biotinylated c3a - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech hm2074
    Hm2074, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm2074/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hm2074 - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech bh6 ic3b
    Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.
    Bh6 Ic3b, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bh6 ic3b/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bh6 ic3b - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech anti c3a des arg
    Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.
    Anti C3a Des Arg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti c3a des arg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti c3a des arg - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech mouse anti c3a
    hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins <t>C3a</t> and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.
    Mouse Anti C3a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti c3a/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti c3a - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    93
    Hycult Biotech hm2074-ia
    hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins <t>C3a</t> and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.
    Hm2074 Ia, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm2074-ia/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hm2074-ia - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    94
    Hycult Biotech monoclonal mouse antibody against human c3a c3a desarg
    ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to <t>C3a</t> and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.
    Monoclonal Mouse Antibody Against Human C3a C3a Desarg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antibody against human c3a c3a desarg/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal mouse antibody against human c3a c3a desarg - by Bioz Stars, 2024-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.

    Journal: Schizophrenia Research

    Article Title: Peripheral immune markers and antipsychotic non-response in psychosis

    doi: 10.1016/j.schres.2020.12.020

    Figure Lengend Snippet: Binary logistic regression predicting response to treatment (Responders vs Non-Responders) covarying for age, gender, BMI and current smoking status.

    Article Snippet: Plates were pre-coated using the following commercial antibodies: Mab2952 (C5a) – Hycult, HM2079, aE11 (TCC) – Hycult, HM2167-1A, NeoBb (Bb) – Quidel, A252, 2991 (C3a) – Hycult, HM2074, BH6 (iC3b)Hycult, HM2168.

    Techniques:

    hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins C3a and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.

    Journal: Antioxidants

    Article Title: Properdin Modulates Complement Component Production in Stressed Human Primary Retinal Pigment Epithelium Cells

    doi: 10.3390/antiox9090793

    Figure Lengend Snippet: hpRPE cells express and secrete complement components. ( A ) mRNA expression of main complement components of the classical ( C1Q ), central ( C3 ) classical/lectin ( C4A , C4B ), terminal ( C5 ) and alternative ( CFB , CFD ) complement pathway was detected in hpRPE cells. hpRPE cells expressed also mRNA of soluble ( CFI , CFH , CFP ) and membrane bound ( CD46 , CD59 ) complement regulators, and transcripts of complement receptors: anaphylatoxin receptors ( C3AR , C5AR1 ), opsonin receptor CR3 subunit ( CD11B ). Shown expression data of donor 1 are representative for mRNA experiments in hpRPE cells of donors 1–4 . ( B ) Activation products of the central complement component C3 [(blot left, arrows) C3b (115 kDa), C3dg (39 kDa) and C3d (35 kDa)] were detected in hpRPE. Multiple bands were identified in hpRPE cells using an anti-complement regulator CFI antibody (blot center, arrows for full CFI (80 kDa) and two CFI disulfide linked chains (50 kDa, 30 kDa)). Anaphylatoxins C3a and C5a (blot right) were found in cell lysates of hpRPE cells. Examples of whole blots are depicted in (B) for donor 5 (C5a) and donor 6 (C3, C3a, CFI). ( C ) hpRPE cells secrete C3, C4, CFB, CFD and the regulators CFI as well as CFH into the cell culture supernatant (pooled data of two eyes, apical and basal supernatant are shown, details for hpRPE cells of donors 11–16 are presented in ). Mean with standard deviation is shown. Dotted line depicts blank control. MFI—mean fluorescence intensity.

    Article Snippet: Membranes were blocked (1 h, 5% bovine serum albumin (BSA)/PBS-T) and incubated with the primary antibodies (overnight, 5% BSA/PBS-T): Rabbit anti-GAPDH-HRP (1:1000, Cell Signaling Technology, Beverly, MA, USA, #3683), mouse anti-C3 (1:100, Progen, Heidelberg, Germany, #61019), goat anti-CFI (1:250, Quidel, San Diego, CA, USA, #A313), mouse anti-C3a (1:50, Hycult, Uden, Netherlands, #HM2074) and mouse anti-C5a-biotin (1:250, Biozol, Eching, Germany, #BLD-518306).

    Techniques: Expressing, Activation Assay, Cell Culture, Standard Deviation, Fluorescence

    ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to C3a and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: ( A ) The complement system is a part of the innate immunity and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of C3 to C3a and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. ( B , C ) The detection of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex ® ). (B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement activation were excluded by utilizing an appropriate reaction buffer.

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques: Activation Assay, Multiplex Assay, Luminex, Magnetic Beads, In Vitro

    ( A ) Serial dilutions of native, human C3a-desArg (black circle), recombinant, human C5a-desArg (black square) and native human sC5b-C9 (black triangle) depicted different assay performances for the simultaneous analysis of complement activation markers. The target antigens were only detected by respective coupled magnetic beads and not by control beads (grey). Limit of detection (orange) and assay cutoffs (red square) for each analyte are shown. ( B ) The concentration range of complement activation markers determined with the novel multiplex assay from a human serum pool (black square with dot) corresponded to previously reported ranges for C3a, C5a and sC5b-C9 single detection either from plasma (grey), serum (black) or unknown sample matrix (white), respectively [ – ].

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: ( A ) Serial dilutions of native, human C3a-desArg (black circle), recombinant, human C5a-desArg (black square) and native human sC5b-C9 (black triangle) depicted different assay performances for the simultaneous analysis of complement activation markers. The target antigens were only detected by respective coupled magnetic beads and not by control beads (grey). Limit of detection (orange) and assay cutoffs (red square) for each analyte are shown. ( B ) The concentration range of complement activation markers determined with the novel multiplex assay from a human serum pool (black square with dot) corresponded to previously reported ranges for C3a, C5a and sC5b-C9 single detection either from plasma (grey), serum (black) or unknown sample matrix (white), respectively [ – ].

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques: Recombinant, Activation Assay, Magnetic Beads, Concentration Assay, Multiplex Assay

    ( A–C ) The histologic grade ( G ) describes the cell differentiation in the patients’ tumors/ neoplasms. Patients with G2 tumor grading had significantly elevated (A) C3a, as well as (B) C5a and (C) sC5b-9 serum levels compared to the control group. ( D–F ) The T-classification system categorizes the extension of the patients′ primary tumors. (D) There was no relation between C3a serum levels and T-classification. (E) All tumor extension classifications (T-classifications) showed a significant increase in systemic C5a levels compared to the control group. (F) Invasive growth (T4) is associated with increased sC5b-9 serum levels compared to the control, T2 and T3 group. ( G–J ) The N-classification describes the degree of spread of tumor cells to regional lymph nodes. (G) C3a concentration was significantly correlated with tumor spread to lymph nodes. C3a concentration was highest in N2 classified lymph node metastases. (H, I) There was no significant correlation between complement markers C5a, sC5b-C9 and lymph node metastases. (J) Patients, that presented a N2-tumor, were significantly younger than patients with a N0 or N1 tumor. ( K–M ) Age was not associated with T-classification or correlated with complement activation marker concentration in serum. ( * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 two-tailed, unpaired t -test).

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: ( A–C ) The histologic grade ( G ) describes the cell differentiation in the patients’ tumors/ neoplasms. Patients with G2 tumor grading had significantly elevated (A) C3a, as well as (B) C5a and (C) sC5b-9 serum levels compared to the control group. ( D–F ) The T-classification system categorizes the extension of the patients′ primary tumors. (D) There was no relation between C3a serum levels and T-classification. (E) All tumor extension classifications (T-classifications) showed a significant increase in systemic C5a levels compared to the control group. (F) Invasive growth (T4) is associated with increased sC5b-9 serum levels compared to the control, T2 and T3 group. ( G–J ) The N-classification describes the degree of spread of tumor cells to regional lymph nodes. (G) C3a concentration was significantly correlated with tumor spread to lymph nodes. C3a concentration was highest in N2 classified lymph node metastases. (H, I) There was no significant correlation between complement markers C5a, sC5b-C9 and lymph node metastases. (J) Patients, that presented a N2-tumor, were significantly younger than patients with a N0 or N1 tumor. ( K–M ) Age was not associated with T-classification or correlated with complement activation marker concentration in serum. ( * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 two-tailed, unpaired t -test).

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques: Cell Differentiation, Concentration Assay, Activation Assay, Marker, Two Tailed Test

    ( A , B , D , F ) Specificity of C3a-beads, ( C , B, D, F) C5a-beads and ( E , B, D, F) sC5b-C9-beads were either analysed in a (A, C, E) one-bead assay with a single antigen dilution series or (B, D, F) all five bead regions and a singular antigen dilution series. (B, D, F) All beads showed a specific signal for the respective antigen and no cross reactivities. The detection of (A, B) C3a, (C, D) C5a and (E, F) sC5b-C9 was comparable in the (A, C, E) single and (B, D, F) multiplex assays, indicating a bead-specific detection.

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: ( A , B , D , F ) Specificity of C3a-beads, ( C , B, D, F) C5a-beads and ( E , B, D, F) sC5b-C9-beads were either analysed in a (A, C, E) one-bead assay with a single antigen dilution series or (B, D, F) all five bead regions and a singular antigen dilution series. (B, D, F) All beads showed a specific signal for the respective antigen and no cross reactivities. The detection of (A, B) C3a, (C, D) C5a and (E, F) sC5b-C9 was comparable in the (A, C, E) single and (B, D, F) multiplex assays, indicating a bead-specific detection.

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques: Multiplex Assay

    ( A–C ) C3a, C5a and sC5b-C9 were quantified either in normal human control serum (control) or C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, properdin-, complement factor H-depleted serum. The lowest concentrations for (A) C3a and (B) C5a were observed in C3-depleted or C5-depleted serum, respectively. (C) The terminal complement complex was detected at a reduced level in C5-depleted serum. We did not observe a detection signal for any of the tested sera on the control beads (data not shown).

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: ( A–C ) C3a, C5a and sC5b-C9 were quantified either in normal human control serum (control) or C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, properdin-, complement factor H-depleted serum. The lowest concentrations for (A) C3a and (B) C5a were observed in C3-depleted or C5-depleted serum, respectively. (C) The terminal complement complex was detected at a reduced level in C5-depleted serum. We did not observe a detection signal for any of the tested sera on the control beads (data not shown).

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques:

    C3a and C5a were either measured in ( A ) aqueous humor of glaucoma and cataract patients, ( B ) in tears of healthy controls or ( C–E ) in sera of OSCC-patients ( n = 57) and matched controls ( n = 46) using the validated 5-plex immunoassay based on luminex technology. (A) The C3a levels of glaucoma and cataract patients did not show any significant difference, but a tendency for higher C3a levels in glaucoma patients. C5a concentrations in aqueous humor were below the lower detection limit. (B) Quantification of C3a and C5a in tears ranged between 4.4–26 ng/mL for C3a and 0.11–3.3 ng/mL for C5a, respectively. (D, E) C5a and sC5b-C9 concentrations were significantly increased in OSCC patients compared to the control group. Mean with standard deviations are depicted. ( ** p < 0.01, **** p < 0.0001 two-tailed, unpaired t -test).

    Journal: Oncotarget

    Article Title: A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma

    doi: 10.18632/oncotarget.22963

    Figure Lengend Snippet: C3a and C5a were either measured in ( A ) aqueous humor of glaucoma and cataract patients, ( B ) in tears of healthy controls or ( C–E ) in sera of OSCC-patients ( n = 57) and matched controls ( n = 46) using the validated 5-plex immunoassay based on luminex technology. (A) The C3a levels of glaucoma and cataract patients did not show any significant difference, but a tendency for higher C3a levels in glaucoma patients. C5a concentrations in aqueous humor were below the lower detection limit. (B) Quantification of C3a and C5a in tears ranged between 4.4–26 ng/mL for C3a and 0.11–3.3 ng/mL for C5a, respectively. (D, E) C5a and sC5b-C9 concentrations were significantly increased in OSCC patients compared to the control group. Mean with standard deviations are depicted. ( ** p < 0.01, **** p < 0.0001 two-tailed, unpaired t -test).

    Article Snippet: The monoclonal mouse antibody against human C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) and the biotinylated monoclonal mouse antibody against human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were obtained from Hycult Biotech (Beutelsbach, Germany).

    Techniques: Luminex, Two Tailed Test